Lonza’s expertise and technical appetite help Epsilogen bring the first IgE therapeutic into the clinic

Tim Wilson, CEO of London-based biotech Epsilogen, discusses the company’s journey to develop a first-in-class IgE therapeutic for solid tumors. He highlights the critical role of partnering with a CDMO that combines strong scientific expertise, track record, and the appetite to take on a type of antibody never before manufactured at scale.